# Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

> **NCT00640627** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 380 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00640627
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2021-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640627, "Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00640627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*